DEMAND FOR DIGNICAP® IS STRONG AS DIGNITANA BRINGS FDA-CLEARED MEDICAL SCALP COOLING DEVICE TO MORE U.S. CANCER CENTERS

Lund, Sweden —June 10, 2016— Dignitana AB, a world leader in medical scalp-cooling technology, announced today that the DigniCap® scalp cooling system, which was recently cleared by the FDA to effectively reduce the likelihood of chemotherapy-induced hair loss in women with breast cancer, is now or will soon be available at 26 cancer treatment centers across the U.S.

The DigniCap® scalp cooling system is the first and only scalp cooling device to complete rigorous FDA clinical trials in the U.S., where seven out of ten patients with early-stage breast cancer kept at least 50% of their hair.

Following FDA Clearance in December 2015, medical centers across the country have begun offering the DigniCap scalp cooling system as part of the comprehensive cancer care treatment services they provide. Through funding from a recent Private Placement and Rights Offering, Dignitana is rapidly expanding its reach across America as demand for the medical device accelerates. Agreements with 26 centers have now been signed*, with some of the early adopters ordering additional units within months of initial set up.

To date, Dignitana has announced installations of the DigniCap® scalp cooling system at the following U.S. medical centers: Bronson Battle Creek Cancer Care Center , Charleston Hematology Oncology Associates , Chesapeake Oncology and Hematology Associates , Florida Cancer Specialists & Research Institute , Menorah Medical Center , Mount Sinai Beth Israel Cancer Center , Mount Sinai Comprehensive Cancer Center , Oncology & Hematology Specialists , Orange County Blood and Cancer Care , The Dubin Breast Center at The Mount Sinai Hospital , Toledo Clinic Cancer Center , Stamford Health Bennett Cancer Center , UCSF Helen Diller Family Comprehensive Cancer Center , UT Health Science Center San Antonio’s Cancer Therapy & Research Center , and Wake Forest Baptist Medical Center .

The following cancer treatment centers are the most recent U.S. sites to include the DigniCap® scalp cooling system as part of their breast cancer treatment care services:

“We are very excited that DigniCap® is being so well-received in the U.S., and that we’ve been able to quickly and effectively fulfil product requests,” said Jan Richardsson, Chief Executive Officer of Dignitana. “From the New York Metropolitan area to communities throughout the midwest, the south, and California, it is clear that DigniCap is filling an important need in quality of life cancer care and medical centers are eagerly promoting its addition to their cancer services.”

The DigniCap® scalp cooling system features a patented tight-fitting silicone cooling cap that is placed directly on the head, and an outer neoprene cap that insulates and secures the silicone cap. The cooling cap is connected to a cooling and control unit with touch screen prompts. A liquid coolant circulates throughout the silicone cap, delivering consistent and controlled cooling to all areas of the scalp. The cap is fitted to the head, and the temperature of the scalp is lowered, resulting in vasoconstriction with reduced delivery of chemotherapy to the scalp, as well as reduced cellular uptake of drugs due to decreased intra follicular metabolic rate. These factors together reduce the risk of chemotherapy-induced hair loss.

* Five sites not listed have chosen to wait until the DigniCap® system has been installed and is in service before disclosing identity

Media Contact:

Jan Richardsson
CEO, Dignitana AB (publ)

Ph   +46 (0)46 16 30 92
E  jan.richardsson@dignitana.com

About Dignitana AB (publ)
Dignitana is a Swedish public company, based in Lund, and manufacturer of the medical cooling device DigniCap®. Dignitana is continuously researching and developing new uses for DigniCap®. Dignitana AB is listed on the OMX Nasdaq First North stock exchange and has appointed Erik Penser Bank as Certified Adviser. For more information visit www.dignitana.com

About the scalp cooling system DigniCap®
Dignitana’s core product - DigniCap® - is a patented scalp-cooling system that offers cancer patients the ability to keep their hair during chemotherapy. DigniCap® is developed to provide continuous cooling with high efficacy, safety and acceptable patient comfort.

Tags:

About Us

Dignitana is a Swedish public company, based in Lund, and manufacturer of the medical cooling device DigniCap®. Dignitana is continuously researching and developing new uses for DigniCap®. Dignitana AB is listed on the OMX Nasdaq First North stock exchange and has appointed Erik Penser Bank as Certified Advisor. For more information visit www.dignitana.com Dignitana’s core product - DigniCap® - is a patented scalp-cooling system that offers cancer patients the ability to keep their hair during chemotherapy. DigniCap® is developed to provide continuous cooling with high efficacy, safety and acceptable patient comfort.

Subscribe

Quotes

We are very excited that DigniCap® is being so well-received in the U.S., and that we’ve been able to quickly and effectively fulfil product requests. From the New York Metropolitan area to communities throughout the midwest, the south, and California, it is clear that DigniCap is filling an important need in quality of life cancer care and medical centers are eagerly promoting its addition to their cancer services.
Jan Richardsson, Chief Executive Officer of Dignitana